Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:ATAI NASDAQ:BEAM NASDAQ:CNTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$10.39-1.0%$10.37$3.85▼$12.43$1.58B1.831.64 million shs1.44 million shsATAIatai Life Sciences$3.23+15.8%$2.26$1.03▼$3.35$647.09M1.442.17 million shs14.82 million shsBEAMBeam Therapeutics$20.75+1.5%$17.97$13.53▼$35.25$2.09B2.071.57 million shs2.16 million shsCNTACentessa Pharmaceuticals$15.69-1.7%$13.17$9.00▼$19.09$2.10B1.45772,953 shs1.01 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-3.05%-13.08%+3.55%+43.25%+141.38%ATAIatai Life Sciences+3.33%+2.20%+25.68%+89.80%+74.38%BEAMBeam Therapeutics+1.89%-7.17%+22.68%+20.29%-24.06%CNTACentessa Pharmaceuticals+1.98%+8.94%+26.67%+29.76%+67.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies2.7889 of 5 stars1.41.00.04.22.72.50.6ATAIatai Life Sciences3.2147 of 5 stars3.84.00.00.02.51.70.6BEAMBeam Therapeutics2.0678 of 5 stars3.50.00.00.02.52.50.6CNTACentessa Pharmaceuticals3.4103 of 5 stars3.54.00.00.02.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.86Moderate Buy$10.571.75% UpsideATAIatai Life Sciences 3.50Strong Buy$9.00178.64% UpsideBEAMBeam Therapeutics 3.00Buy$48.75134.94% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.8977.75% UpsideCurrent Analyst Ratings BreakdownLatest ATAI, ADPT, CNTA, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025ATAIatai Life SciencesAegisSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/2/2025ATAIatai Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.006/18/2025ADPTAdaptive BiotechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.005/28/2025CNTACentessa PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.005/20/2025ATAIatai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/13/2025ATAIatai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.005/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M8.82N/AN/A$1.37 per share7.58ATAIatai Life Sciences$1.86M347.34N/AN/A$0.69 per share4.68BEAMBeam Therapeutics$63.52M32.85N/AN/A$8.86 per share2.34CNTACentessa Pharmaceuticals$6.85M305.90N/AN/A$3.05 per share5.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%8/5/2025 (Estimated)ATAIatai Life Sciences-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)BEAMBeam Therapeutics-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)CNTACentessa Pharmaceuticals-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)Latest ATAI, ADPT, CNTA, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ATAIatai Life Sciences-$0.13N/AN/AN/AN/AN/A8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.34N/AN/AN/AN/AN/A8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24N/AN/AN/AN/AN/A8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04N/AN/AN/A$13.29 millionN/A5/14/2025Q1 2025ATAIatai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million5/1/2025Q1 2025ADPTAdaptive Biotechnologies-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AATAIatai Life SciencesN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.922.82ATAIatai Life Sciences0.084.074.07BEAMBeam TherapeuticsN/A8.818.81CNTACentessa Pharmaceuticals0.2814.3714.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%ATAIatai Life Sciences28.41%BEAMBeam Therapeutics99.68%CNTACentessa Pharmaceuticals82.01%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%ATAIatai Life Sciences26.80%BEAMBeam Therapeutics3.50%CNTACentessa Pharmaceuticals7.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790151.92 million142.19 millionOptionableATAIatai Life Sciences80200.34 million146.65 millionOptionableBEAMBeam Therapeutics510100.56 million97.04 millionOptionableCNTACentessa Pharmaceuticals200133.55 million124.09 millionOptionableATAI, ADPT, CNTA, and BEAM HeadlinesRecent News About These CompaniesWildcat Capital Management LLC Invests $4.05 Million in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)July 17 at 9:48 AM | marketbeat.comCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of "Buy" by AnalystsJuly 16 at 2:48 AM | marketbeat.comCentessa Pharmaceuticals Advances Neurological Drug ORX142 to Clinical TrialsJuly 15 at 11:41 AM | msn.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 7.9% - Still a Buy?July 9, 2025 | marketbeat.comCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Shares Bought by HighMark Wealth Management LLCJune 27, 2025 | marketbeat.comCNTA Centessa Pharmaceuticals plc - Seeking AlphaJune 27, 2025 | seekingalpha.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.8% on Insider SellingJune 26, 2025 | marketbeat.comInsider Selling: Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells 10,000 Shares of StockJune 26, 2025 | insidertrades.comCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells $138,600.00 in StockJune 25, 2025 | marketbeat.comIqbal J. Hussain Sells 12,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) StockJune 25, 2025 | marketbeat.comInsider Selling: Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells 15,000 Shares of StockJune 25, 2025 | marketbeat.comCentessa Pharmaceuticals plc's (NASDAQ:CNTA) Intrinsic Value Is Potentially 99% Above Its Share PriceJune 24, 2025 | finance.yahoo.comCentessa Pharmaceuticals Receives FDA Clearance for New Drug ORX142, Initiates Phase 1 StudyJune 24, 2025 | msn.comCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Sells $694,650.00 in StockJune 21, 2025 | insidertrades.comCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Buy" by AnalystsJune 21, 2025 | marketbeat.comSaurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) StockJune 20, 2025 | marketbeat.comCentessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep ...June 18, 2025 | seekingalpha.comCentessa announces clearance of IND for ORX142June 18, 2025 | finance.yahoo.comCentessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?June 16, 2025 | zacks.comCentessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this YearJune 16, 2025 | globenewswire.comWall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a BetJune 4, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATAI, ADPT, CNTA, and BEAM Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$10.39 -0.11 (-1.05%) Closing price 04:00 PM EasternExtended Trading$10.62 +0.23 (+2.21%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.atai Life Sciences NASDAQ:ATAI$3.23 +0.44 (+15.77%) Closing price 04:00 PM EasternExtended Trading$3.24 +0.02 (+0.46%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Beam Therapeutics NASDAQ:BEAM$20.75 +0.30 (+1.47%) Closing price 04:00 PM EasternExtended Trading$20.88 +0.13 (+0.60%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Centessa Pharmaceuticals NASDAQ:CNTA$15.69 -0.27 (-1.69%) Closing price 04:00 PM EasternExtended Trading$15.68 -0.01 (-0.10%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.